Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has ...
Since Leqembi is dosed based on a patient’s weight and offered in single-use vials, about 5.8% of the drug dispensed will be ...
Australia's Therapeutic Goods Administration (TGA) has said it won't approve Eisai and Biogen's Alzheimer's disease therapy ...
A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...
A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...
Prothena Corporation plc's stock has dropped 67% since my last “Buy” rating, primarily due to delays and a lack of meaningful ...
Neurophet to host Symposium featuring renowned expert in Alzheimer's disease treatment from the U.S.
Neurophet has specialized in developing solutions for diagnosis support, treatment guides, and treatment devices targeting ...
Detailed price information for Annovis Bio Inc (ANVS-N) from The Globe and Mail including charting and trades.
This week marked the start of the third-quarter earnings season, with Johnson & Johnson exceeding Wall Street’s expectations.
New research suggests that Medicare could save up to 74 percent of the money lost from discarded Alzheimer's drug Leqembi or ...
About 6% of Leqembi (lecanemab) is discarded because patients are frequently prescribed doses lower than the size of the drug’s single-use vials. This waste costs Medicare about $1,600 a patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback